Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin) and Pembrolizumab (Anti-PD1, Keytruda) for Therapy of Metastatic Kidney Cancer
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 11 Oct 2024 Planned End Date changed from 1 Aug 2024 to 1 Oct 2024.
- 31 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Aug 2024.
- 15 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.